Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 49

1.

High-throughput screening of chromatin immunoprecipitates using CpG-island microarrays.

Oberley MJ, Tsao J, Yau P, Farnham PJ.

Methods Enzymol. 2004;376:315-34. Review. No abstract available.

PMID:
14975315
2.

A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer.

Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME.

Cell. 2003 Aug 8;114(3):323-34.

3.

E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9.

Oberley MJ, Inman DR, Farnham PJ.

J Biol Chem. 2003 Oct 24;278(43):42466-76. Epub 2003 Aug 8.

4.

Gene expression phenotypic models that predict the activity of oncogenic pathways.

Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, D'Amico M, Pestell RG, West M, Nevins JR.

Nat Genet. 2003 Jun;34(2):226-30.

PMID:
12754511
5.

Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor.

Giangrande PH, Hallstrom TC, Tunyaplin C, Calame K, Nevins JR.

Mol Cell Biol. 2003 Jun;23(11):3707-20.

6.

Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase.

Wells J, Yan PS, Cechvala M, Huang T, Farnham PJ.

Oncogene. 2003 Mar 13;22(10):1445-60.

PMID:
12629508
7.

The transcriptional activity of human Chromosome 22.

Rinn JL, Euskirchen G, Bertone P, Martone R, Luscombe NM, Hartman S, Harrison PM, Nelson FK, Miller P, Gerstein M, Weissman S, Snyder M.

Genes Dev. 2003 Feb 15;17(4):529-40.

8.

The retinoblastoma tumour suppressor in development and cancer.

Classon M, Harlow E.

Nat Rev Cancer. 2002 Dec;2(12):910-7. Review.

PMID:
12459729
9.

Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function.

Schlisio S, Halperin T, Vidal M, Nevins JR.

EMBO J. 2002 Nov 1;21(21):5775-86.

10.

Transcriptional regulatory networks in Saccharomyces cerevisiae.

Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z, Gerber GK, Hannett NM, Harbison CT, Thompson CM, Simon I, Zeitlinger J, Jennings EG, Murray HL, Gordon DB, Ren B, Wyrick JJ, Tagne JB, Volkert TL, Fraenkel E, Gifford DK, Young RA.

Science. 2002 Oct 25;298(5594):799-804.

11.

E2F1 pathways to apoptosis.

Ginsberg D.

FEBS Lett. 2002 Oct 2;529(1):122-5. Review.

12.

Homeotic transformations of the axial skeleton that accompany a targeted deletion of E2f6.

Storre J, Elsässer HP, Fuchs M, Ullmann D, Livingston DM, Gaubatz S.

EMBO Rep. 2002 Jul;3(7):695-700.

13.
14.

Large-scale transcriptional activity in chromosomes 21 and 22.

Kapranov P, Cawley SE, Drenkow J, Bekiranov S, Strausberg RL, Fodor SP, Gingeras TR.

Science. 2002 May 3;296(5569):916-9.

15.

Gene expression changes in response to E2F1 activation.

Stanelle J, Stiewe T, Theseling CC, Peter M, Pützer BM.

Nucleic Acids Res. 2002 Apr 15;30(8):1859-67.

16.

Mutant mouse models reveal the relative roles of E2F1 and E2F3 in vivo.

Cloud JE, Rogers C, Reza TL, Ziebold U, Stone JR, Picard MH, Caron AM, Bronson RT, Lees JA.

Mol Cell Biol. 2002 Apr;22(8):2663-72.

17.

The identification of E2F1-specific target genes.

Wells J, Graveel CR, Bartley SM, Madore SJ, Farnham PJ.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3890-5.

18.

Identification of novel E2F1-regulated genes by microarray.

Ma Y, Croxton R, Moorer RL Jr, Cress WD.

Arch Biochem Biophys. 2002 Mar 15;399(2):212-24.

PMID:
11888208
19.

Direct repression of the Mcl-1 promoter by E2F1.

Croxton R, Ma Y, Song L, Haura EB, Cress WD.

Oncogene. 2002 Feb 21;21(9):1359-69.

20.

Sibling rivalry in the E2F family.

Trimarchi JM, Lees JA.

Nat Rev Mol Cell Biol. 2002 Jan;3(1):11-20. Review.

PMID:
11823794

Supplemental Content

Support Center